Tolerance to the foetal 'allograft' has been extensively studied in the past few years, providing interesting new insights. In addition to a potential role for HLA-G, which has been widely discussed, there are hypotheses suggesting roles for several other molecules or cells: leukemia inhibitory factor and its receptor; indoleamine 2.3-dioxygenase; the Th1/Th2 balance; suppressor macrophages; hormones such as progesterone or the placental growth hormone; CD95 and its ligand; and, as recently proposed, annexin II. Tolerance of the foetal allograft is probably the consequence of a wide panel of mechanisms that may or may not be pregnancy-specific, that are of major or secondary importance and that may be interconnected.
Introduction: tolerance to the foetus
The conceptus genome is half-paternal and half-maternal. It is thus logical to presume that the immune system of the mother should reject it, as it does every paternal graft [1] , but this generally does not occur. Tolerance of the semiallogenic foetal 'graft' by the maternal immune system is a medical enigma that has stimulated research for half a century. Indeed, in 1953 Billingham and Medawar published an article in Nature in which this question was discussed [2] . Four hypotheses were proposed by the authors: that the conceptus lacked immunogenicity; that there was a significant lowering of immune response during pregnancy; that the uterus is an immunoprivileged site; and that there is the elaboration of an immune barrier by the placenta.
Through the years, the first three hypotheses have been abandoned. Indeed, studies of Hoskin and Murgita [3] revealed an immune reaction against foetal cells in the mouse and showed that the conceptus possesses immunogenic properties. Medical observations of pregnant women and studies of their immune status and of the response of their immune cells to various stimuli proved that the immune response of pregnant women is not significantly reduced in comparison with that of non-pregnant women. Finally, the possibility of ectopic pregnancies demonstrates that the uterus does not uniquely protect the conceptus as an immunoprivileged site.
The fourth hypothesis, suggesting the existence of an immune barrier elaborated by the placenta, is still considered -but in another form. Originally, this barrier was presumed to be passive or neutral but later, as reviewed by Petraglia et al. [4] , the placenta was shown to be a site of active tolerance. Therefore, tolerance to the semi-allogenic foetus by the maternal immune system seems mainly an active mechanism whereby foetal tissues are prevented from being recognised as foreign tissue and/or from being rejected by the cells of the maternal immune system. In this article, we summarise ten factors that have been advanced as candidates in hypotheses to explain this phenomenon. Their order reflects to a large extent how established their roles have become.
Hypotheses to explain maternal tolerance of the foetus
Since half of the foetal genome derives from the father, the foetus synthesises antigens considered to be foreign by the maternal immune system [1] . Furthermore, foetal cells, and thus potentially immunogenic foetal antigenic molecules, may be detected in the maternal blood [5] . It is presumed that these cells and molecules are released into the maternal blood during proliferation of trophoblastic cells, following tissue ruptures that occur at the terminal extremity of the growing chorial villi. The whole immune system comes into contact with these potential foetal immunogens and, in spite of this, the conceptus is tolerated and pregnancy reaches its term without any major immunological problem in the greatest majority of cases. Nevertheless, Hoskin and Murgita [3] have shown that splenocytes of primiparous mice proliferate following exposure to foetal cells whereas those of virgin mice do not. This indicates that, in the mouse, the maternal immune system is potentially able to recognise and react against foetal antigens. During normal pregnancy, however, this response capacity does not have negative consequences.
So we are confronted with a two-tiered regulatory system: firstly, effects occur on the whole maternal immune system, probably and principally mediated through soluble endocrine factors; secondly, at a local level, effects occur during the direct contact of maternal and foetal cells in the Tolerance to the foeto-placental 'graft': ten ways to support a child for nine months Olivier Thellin*, Bernard Coumans*, Willy Zorzi*, Ahmed Igout † and Ernst Heinen* placenta, principally through cellular contacts, or paracrine and autocrine soluble factors.
The ten factors that we outline below, and the resulting hypotheses concerning their role in the phenomenon of tolerance to the foetal allograft, seem to implicate different mechanisms working in synergy.
HLA-G expression by the trophoblast
In humans, the syncytiotrophoblast, which constitutes the foetal syncytial layer isolating the foetal tissues from the maternal tissues, expresses a very particular set of MHC class I molecules. Indeed, HLA-A and HLA-B are not presented by the syncytiotrophoblastic cells whereas HLA-C seems weakly expressed [6, 7] . On the other hand, these cells express HLA-G ( [8] ; see also Update); this class I molecule is encountered only on the syncytiotrophoblast and is nearly monomorphic -only two forms of this molecule are currently known. Recently, HLA-G has been found to bind the KIRs (killer-cell immunoglobulin-like receptors) of NK cells, as the other HLA molecules do. This interaction appears to block the cytotoxicity of these cells ( Figure 1 ) and may contribute to the tolerance of the conceptus by reducing NK cell activity [9] . The nearly monomorphic status of HLA-G suggests a general inhibition of NK cells, independent of the parental genomes.
Leukemia inhibitory factor and its receptor
The maternal endometrium synthesises and secretes a hydrosoluble molecule called leukemia inhibitory factor (LIF) following a menstrual cycle related to the progesterone cycle [10] . During implantation, the endometrium secretes LIF whereas the blastocyst expresses at its surface the LIF-receptor (LIF-R) [11, 12] (Figure 2a ). This is absolutely required for blastocyst implantation. During pregnancy, LIF is synthesised by the decidua -the maternal part of the placenta -and by Th2 lymphocytes whereas the syncytiotrophoblast expresses LIF-R [13] ( Figure 2b ). The exact function of the LIF/LIF-R molecules during pregnancy is still unknown but the binding of LIF on its receptor might favour trophoblastic growth and differentiation [14] . This mechanism is also closely related to other immune mechanisms implicated in the foetomaternal tolerance, such as the Th1/Th2 balance and regulation by progesterone.
Indoleamine 2,3-dioxygenase
Indoleamine 2,3-dioxygenase (IDO) is an enzymatic protein that catabolises tryptophan. This enzyme is synthesised and secreted by the syncytiotrophoblast and has been shown to be essential for the success of pregnancy in the mouse [15, 16] . A proposed explanation for its role in tolerance of the foetus is that IDO could act by catalysing tryptophan destruction in maternal immune cells that are localised in the placental area; this tryptophan deprivation might reduce or inhibit some immune cell responses ( Figure 3 ). The Th1/Th2 balance in the placenta has been studied and results have shown that a Th1-type reaction in the placenta, which mainly generates inflammatory responses, is often correlated with miscarriages whereas a Th2 cell induction generates noninflammatory responses that are compatible with the survival of the foetus [13, [18] [19] [20] . Th1 and Th2 cells exert different actions. Th1 cells synthesise IL-2 and IFN-γ whereas Th2 cells preferentially synthesise IL-4, IL-5, IL-6, IL-9, IL-10 (see also Update) and IL-13. Th1 and Th2 cells also share the production of some cytokines like IL-3, TNF and GM-CSF.
T cells are, however, not the only producers of cytokines. Notably here, syncytiotrophoblasts and cytotrophoblasts are able to produce cytokines; these cells can also influence cytokine production, by acting on Th1/Th2 balance [21, 22] . They generally direct to a Th2-type response in the peri-implantatory site of the endometrium [23] and during pregnancy (Figure 4 ) [24] .
Suppressor macrophages
Placental macrophages that protect the immunologically privileged embryo occur naturally [25] . Today these suppressor macrophages are considered to be 'alternatively' activated macrophages that are able to exert anti-inflammatory influences in various sites of the body. In contrast to 'classically' activated macrophages that have pro-inflammatory potency, for example those induced by IFN-γ or lipopolysaccharides, the alternatively activated macrophages produce little to no free oxygen derivatives but produce more of the anti-inflammatory molecules IL-10 and IL-1-Rantagonist (see [26] for a review).
Hormones
Numerous hormones and cytokines are present and active at the placenta (for a review, see [4] ). They act on the trophoblastic tissues in many ways and some of them modulate immune functions.
An important molecule is progesterone, which is synthesised in large quantities by the placenta and is able to lower the immune response [27] . The precise effects of this hormone on foetal tolerance have been described. Progesterone is able to promote LIF synthesis by the endometrium [10] and to displace the Th1/Th2 balance (see above) towards Th2 [28] (Figure 4) ; however progesterone is not the only hormone able to act on the immune system.
Growth hormone appears likewise, in some rodent species, to influence certain functions of the immune system. It is important to note that the human placenta synthesises a particular growth hormone, human placental growth hormone (hPGH), differing in only 13 amino acids from pituitary growth hormone (hGH-N); hPGH replaces hGH-N in the maternal blood during the second half of the pregnancy [29, 30] . hPGH is abundantly produced during pregnancy and could play an active role in foeto-placental tolerance by acting on the maternal immune system. Experiments in which hGH-N or hPGH were introduced at physiological concentrations into the culture medium of lymphoid cells indicated that the actions of hGH-N and hPGH on cell proliferation and the production of cytokines are equivalent [31] . Because of its structural, binding and physiological differences relative to hGH-N, it is possible that hPGH-specific effects may be found in the future, both in vitro and in vivo. A potential role of the Th1/Th2 balance in tolerance to the foetus. A successful pregnancy is more often correlated with a Th2-than with a Th1-type neighbourhood. Besides, the syncytiotrophoblast secretes hormones and various cytokines that influence the Th1/Th2 balance, mainly towards Th2. 
CD95 and its ligand
The CD95/CD95-ligand (CD95-L) system is an apoptotic pathway widely used in the immune system during lymphopoiesis and immunopoiesis. It is mainly implicated in regulation of cellular turnover, tumor cell elimination, antiviral responses and protection of particular tissues against potential danger represented mainly by activated lymphocytes [32] . It is also active during clonal deletion of autoimmune cells inside the central and peripheral lymphoid organs and is involved in the cytolytic pathways of NK cells, Th1 cells and cytotoxic T cells. This cytolysis occurs in parallel with perforin production by NK cells and cytotoxic T cells.
This system functions as follows: CD95-L is expressed by effector cells whereas the target cells express CD95. For protection of particular tissues, CD95-L is expressed by the cells that delineate the immunoprivileged site. For example, CD95/CD95-L are active in the protection of certain parts of the eye [33, 34] and CD95-L has been detected on the surface of rat Sertoli cells [35] and, more recently, inside human testis [32] . We and other groups have proposed that CD95-L is expressed by trophoblastic cells and is able to kill the activated, CD95 + blood cells that enter into contact with the conceptus ( Figure 5 ).
In parallel with other groups [32, 36] , we have indeed shown that trophoblastic cells synthesise CD95-L in vivo and in vitro [37] . Cultured trophoblastic cells are able to induce apoptosis in blood T cells expressing CD95 [38] . It is notable that trophoblastic cells also express CD95 ( [39] ; O Thellin, B Coumans, E Heinen, unpublished data) but apparently do so without full apoptotic consequences for these cells [40] . This CD95 expression could play a role in limiting the proliferation of the trophoblast. Our results also suggest that only a part of the observed apoptosis occurs effectively via the CD95/CD95-L pathway; the TNF/TNF-R apoptotic system, which is also present at the placenta [4] , could be involved in tolerance to the foetus. By in vivo observation, Jerzak et al. [41] detected apoptotic T lymphocytes in human decidua during the first trimester; this supports our hypothesis related to the active elimination of potentially dangerous T cells by trophoblastic cells.
Furthermore, proteolysis of cell surface CD95-L, mediated by a membrane metalloproteinase, produces a 26 kDa soluble form of the CD95-L [42] [43] [44] . This molecule is biologically active [45] and could also trigger apoptosis of immune cells near to, or coming into contact with, the foetal cells.
Annexin II
Annexin II is a member of a family of glycoproteins that bind to negatively charged phospholipids in a calciumdependent manner. Annexins are membrane-associated proteins that are expressed in both normal and malignant cells and can also be secreted by the placenta [46] . Recently, Aarli and Matre [47] showed that annexin II can partially inhibit lymphoproliferation of, and IgG and IgM secretion by, maternal immune cells ( Figure 6 ). Thus, this molecule might be involved in protection of the foetus against the maternal immune system.
Lowered complement activity
A way commonly used by the immune system to kill foreign or cancerous cells is to activate the complement system. Certain antibody isotypes bind to their membrane antigen and initiate the complement cascade, leading to the assembly of the membrane attack complex; this creates a hole in the target cell, which then dies quickly. So, recognition of paternal antigens on the surface of syncytiotrophoblast could activate the complement cascade, resulting in death of trophoblastic cells. Certain molecules are able to reduce this phenomenon, either by blocking the binding sites of the complement to antibodies (e.g. membrane complement protein [MCP] does this) [48] or by raising the complement destruction rate (e.g. decay accelerating factor [DAF] does this) [49] (Figure 7 ). These molecules have systemic effects. In the placenta, they could reduce the ability of complement to kill trophoblastic cells that bear paternal antigens (see also Update).
Hidden trophoblastic antigens
It has been suggested that trophoblastic antigens expressed by the syncytiotrophoblast are camouflaged, thus avoiding the maternal immune system [50] ; however, this hypothesis is very speculative. There are numerous possibilities for the mechanism of camouflage, including foetal-antigenspecific blocking antibodies and fibrinoid material or sialomucines, which may 'cover' foetal antigens. Anti-idiotypic antibodies that block antibodies directly aimed at the foetal antigens could also be implicated [51] . Hiding of the trophoblastic antigens suggests a reduction of the antigenicity of the syncytiotrophoblast. 
Conclusions
As reviewed here, many very different mechanisms play a part in foeto-placental tolerance; however, their relative importance in other aspects of pregnancy may differ. Indeed, progesterone and LIF/LIF-R are necessary for blastocyst implantation. Progesterone also plays a major role during implantation and gestation; it can act locally and at a distance.
Other mechanisms, such as those involving IDO, HLA-G, CD95/CD95-L and the complement-inhibiting molecules exert their effects primarily on the immune system.
The factors outlined above involve one molecule that is only found at the placenta (HLA-G) whereas other mechanisms act elsewhere in the organism (complement regulation, IDO, Th1/Th2, certain hormones, CD95/CD95-L and annexin II; see also Update).
These mechanisms mainly work in parallel but some of them could also help to restrain negative effects of other ones. For example, CD95-L acts as chemotactant for the granulocytes [52] (this could explain how these cells are mobilized against CD95-L-expressing grafts [53, 54] ) whereas pituitary growth hormone has been shown to inhibit the chemotaxis of neutrophils [55] . hPGH, which is produced in high amounts by the foetal part of the placenta, may protect the foetal tissues against an invasion by maternal neutrophils that are attracted by CD95-L. The redundant mechanisms that are involved in tolerance to the conceptus allow successful pregnancy even when women are deficient for one of these mechanisms.
In summary, maternal tolerance of the foeto-placental graft is the result of the integration of numerous mechanisms of various origins and modes of action; however only some of these mechanisms may really be important for the success of the pregnancy.
Update
Recently, the anti-inflammatory cytokine IL-10, produced notably in the placenta, has been shown to increase HLA-G synthesis in vitro in peripheral-blood monocytes and in trophoblast organ culture, and is thus a good candidate as a stimulator of HLA-G synthesis in the trophoblast in vivo [56] .
Regulation of complement could be more important than previously expected, as mice with a knockout of Crry (a rodent-specific complement regulator) die in utero. These embryos appear to contain C3 deposited on the placenta, indicating complement activation ( [57] ; see [58] for review).
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Figure 6
A potential role of annexin II in tolerance to the foetus. 
